STOCK TITAN

Silk Road Medical to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SUNNYVALE, Calif., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the upcoming 40th Annual J.P. Morgan Healthcare Conference.

Silk Road Medical’s management is scheduled to present on Wednesday, January 12, 2022 at 3:45 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: https://investors.silkroadmed.com/

About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.

Investor Contact:
Lynn Lewis or Marissa Bych
Gilmartin Group
investors@silkroadmed.com


Silk Road Medical Inc

NASDAQ:SILK

SILK Rankings

SILK Latest News

SILK Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Medical Specialties, Health Technology, Manufacturing, Surgical and Medical Instrument Manufacturing
United States
Sunnyvale

About SILK

silk road medical, inc. is a privately held company located in sunnyvale, california, dedicated to preventing the devastating burden of stroke through surgical innovation. the company develops and manufactures less-invasive medical devices to improve the treatment of vascular disease through proprietary transcarotid therapies. by innovating around proven surgical principles and developing breakthrough technology for vascular specialists, we can improve the lives of people with carotid artery disease. our history is one of deep collaboration with vascular specialists and our future will be guided by continuous learning, observation and improvement. for more information on the company, visit our website at http://silkroadmed.com/. the transcarotid artery revascularization (tcar) procedure is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. th